Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,789
Out of 5,241 analysts
7
Total ratings
12.5%
Success rate
-47.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.35 | +1,751.85% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $0.52 | +1,824.19% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $10.23 | -21.80% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $28.05 | +199.47% | 1 | Aug 16, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $9.75 | +12.82% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $0.63 | +3,243.95% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $13.16 | +6,738.91% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.35
Upside: +1,751.85%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $0.52
Upside: +1,824.19%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $10.23
Upside: -21.80%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $28.05
Upside: +199.47%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $9.75
Upside: +12.82%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $0.63
Upside: +3,243.95%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $13.16
Upside: +6,738.91%